INmune Bio, Inc.
INMB
$1.97
-$0.01-0.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -151.13% | -5.65% | 23.77% | -24.08% | 11.60% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -60.00% | -37.50% | -29.41% |
| Total Other Non-Cash Items | 769.36% | 18.16% | 2.21% | -26.85% | 32.10% |
| Change in Net Operating Assets | -215.02% | 123.58% | -205.48% | 756.23% | -129.61% |
| Cash from Operations | -8.07% | 38.04% | -57.64% | 11.41% | -5.48% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 322.28% | 1,149.76% | -96.57% | -20.68% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 322.28% | 353.80% | -121.22% | -24.66% | 619.88% |
| Foreign Exchange rate Adjustments | -337.14% | -107.59% | 242.72% | -634.09% | -133.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 985.62% | 87.45% | -608.66% | -51.00% | 151.46% |